About this Initiative

The slow adoption of biosimilars in the U.S. has been attributed to various barriers, including those related to awareness, prescriber and patient concerns, limited labeling allowances for some indications, and lack of incentives to switch. To enhance adoption of biosimilars in a range of therapeutic areas, ASHP and the ASHP Foundation engaged a group of stakeholders in a coordinated initiative designed to develop a deeper understanding of current trends, understand health-system challenges and opportunities, and identify best practices learned from early adopters of biosimilars.
Furthermore, the project sought to explore pharmacists’ roles to stimulate implementation of biosimilars in a range of practice settings and therapeutic areas.The findings are presented in the Accelerating the Adoption of Biosimilars report and will be discussed in a 1-hour webinar and podcast by members of the Steering Committee.